Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Abilify Maintena

    - PMLiVE

    Alkermes’ new antipsychotic clears FDA advisory committee hurdle

    Target action date for FDA decision is due on 15 November

    - PMLiVE

    Lundbeck drops Parkinson’s drug acquired in €905m deal

    Disappointment after drug failed in a mid-stage clinical trial

    - PMLiVE

    Lundbeck gets US approval for migraine drug at heart of Alder takeover

    US regulator clears CGRP inhibitor under Vyepti trade name

    - PMLiVE

    Troubled Alkermes eyes November OK for new antipsychotic

    Review begins for potential schizophrenia and bipolar I disorder drug

    - PMLiVE

    Merck strengthens KRAS stake with Taiho and Astex partnership

    Partner companies could gain $2.5bn in milestone payments

    - PMLiVE

    Intra-Cellular soars on FDA approval of schizophrenia drug

    Shares rocketed following the announcement

    - PMLiVE

    Karuna’s shares spike on schizophrenia drug data

    Value leaps to more than $1bn following mid-stage trial results

    - PMLiVE

    Otsuka presses on with Alzheimer’s agitation drug

    Surprise announcement comes on the heels of phase 3 trial fail

    - PMLiVE

    Avanir’s week goes from bad to worse with Alzheimer’s stumble

    Suffers a blow as second phase 3 trial misses the mark

    - PMLiVE

    Lundbeck bolts on migraine drug via $1.95bn deal to buy Alder

    Continues to bulk up its pipeline

    - PMLiVE

    Lundbeck’s key products shine in Q2 but problems remain

    Faces increasing patent losses

    - PMLiVE

    Verily unveils next-gen trials alliance with Novartis, Pfizer

    New data methods and tech will be used to streamline trials

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links